NMDA receptor genotypes associated with the vulnerability to develop dyskinesia

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Ivanova, S A ^a   Loonen, A J M ^b,c   Pechlivanoglou, P ^b   Freidin, M B ^d,e   Al Hadithy, A F Y ^b,f   Rudikov, E V ^a   Zhukova, I A ^g   Govorin, N V ^h   Sorokina, V A ⁱ   Fedorenko, O Y ^a   Alifirova, V M ^g   Semke, A V ^a   Brouwers, J R B J ^b   Wilffert, B ^b  

^a MENTAL HEALTH RESEARCH INSTITUTE   (Russian Federation)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Department of Severe Mental Illness   (Netherlands)

^d RESEARCH INSTITUTE OF MEDICAL GENETICS   (Russian Federation)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^h CHITA STATE MEDICAL ACADEMY   (Russian Federation)

ⁱ Kemerovo Regional Clinical Psychiatric Hospital   (Russian Federation)

Author keywords

extra pyramidal; GRIN2A; levodopa induced dyskinesia; medium spiny neuron; NMDA; tardive dyskinesia

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; N METHYL D ASPARTATE RECEPTOR SUBTYPE 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NEUROLEPTIC AGENT;

ALLELE; ARTICLE; DYSKINESIA; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; HUNTINGTON CHOREA; LONG TERM CARE; MOTOR CORTEX; MOTOR DYSFUNCTION; ONSET AGE; PATHOPHYSIOLOGY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE OF ONSET; ALLELES; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HUNTINGTON DISEASE; LEVODOPA; LONG-TERM CARE; MOTOR CORTEX; MOVEMENT DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84856263449     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2011.66     Document Type: Article

References (25)

1. Kane JM. Tardive dyskinesia circa 2006. Am J Psychiatry 2006; 163: 1316-1318.
2. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. part 1: Pathophysiology and mechanisms of induction. Can J Psychiatry 2005; 50: 541-547. (Pubitemid 43161786)
3. Novak MJ, Tabrizi SJ. Huntington's disease. BMJ 2010; 340: c3109.
4. Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in parkinson's disease: Clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007; 83: 384-388. (Pubitemid 46960824)
5. Estrada Sanchez AM, Mejia-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of huntington's disease. Arch Med Res 2008; 39: 265-276. (Pubitemid 351221151)
6. Fan MM, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in huntington's disease. Prog Neurobiol 2007; 81: 272-293. (Pubitemid 46528641)
7. Kumar P, Kalonia H, Kumar A. Huntington's disease: Pathogenesis to animal models. Pharmacol Rep 2010; 62: 1-14.
8. Groenewegen HJ. The basal ganglia and motor control. Neural Plast 2003; 10: 107-120.
9. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 17: 47-62. (Pubitemid 36044348)
10. Konitsiotis S, Tsironis C, Kiortsis DN, Evangelou A. Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias. Psychopharmacology (Berl) 2006; 185: 369-377.
11. Arning L, Kraus PH, Valentin S, Saft C, Andrich J, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in huntington disease. Neurogenetics 2005; 6: 25-28. (Pubitemid 40394827)
12. Andresen JM, Gayan J, Cherny SS, Brocklebank D, Alkorta-Aranburu G, Addis EA et al. Replication of twelve association studies for huntington's disease residual age of onset in large venezuelan kindreds. J Med Genet 2007; 44: 44-50. (Pubitemid 46142838)
13. Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in huntington disease in a sex-specific manner. Hum Genet 2007; 122: 175-182. (Pubitemid 47241782)
14. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255-262.
15. Loonen AJ, van Praag HM. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. J Clin Psychopharmacol 2007; 27: 423-430. (Pubitemid 47415038)
16. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487. (Pubitemid 12152819)
17. Xu Z, Taylor JA. SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37: W600-W605.
18. Kooperberg C, Ruczinski I. Identifying interacting SNPs using monte carlo logic regression. Genet Epidemiol 2005; 28: 157-170.
19. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644-645. (Pubitemid 46522604)
20. Cherlyn SY, Woon PS, Liu JJ, Ong WY, Tsai GC, Sim K. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: A decade of advance. Neurosci Biobehav Rev 2010; 34: 958-977.
21. Liou YJ, Wang YC, Chen JY, Bai YM, Lin CC, Liao DL et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res 2007; 153: 271-275.
22. Lee JY, Cho J, Lee EK, Park SS, Jeon BS. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in parkinson's disease. Mov Disord 2011; 26: 73-79.
23. Shadrina MI, Slominsky PA, Limborska SA. Molecular mechanisms of pathogenesis of parkinson's disease. Int Rev Cell Mol Biol 2010; 281: 229-266.
24. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001; 16: 515-520. (Pubitemid 36041158)
25. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999; 22: 273-276. (Pubitemid 29506396)